Urology practice marketing beyond ED

A urology practice treats conditions that patients search for in very different moods. Someone with a kidney stone is in pain and wants care today. A man reading about an enlarged prostate may have put off a visit for months. A couple looking up vasectomy is making a planned, permanent decision. Each of those searches needs a different kind of page, and each comes with its own rules about what you can claim.

This guide covers urology marketing beyond erectile dysfunction: condition pages, kidney stone access, prostate care and device wording, prostate cancer screening language, vasectomy pages, patient stories and ads. If your practice also markets ED care or a men’s health clinic, our guide to male health and ED clinic marketing covers that ground, including Google’s sexual health ad rules, and we do not repeat it here. For shared decision pages and free PSA events, see prostate cancer screening outreach. For incontinence clinic claims, see bladder clinic marketing.

This is general information, not legal or medical advice. Sources cited were checked on October 29, 2026: NIDDK pages on kidney stones (last reviewed May 2017) and benign prostatic hyperplasia (last reviewed June 2024), MedlinePlus on vasectomy (review date January 12, 2026), Medicare.gov on prostate cancer screenings, the USPSTF prostate cancer screening recommendation (archived copy of October 23, 2026), 21 CFR 807.97, 876.4340, 876.4350, 876.5530 and 876.5990, the FTC Health Products Compliance Guidance, 16 CFR 255.2, 15 U.S.C. 45, 45 CFR 164.508 and Google Ads policies. Have your clinical leadership and counsel review your own pages.

Build pages around the conditions patients search for

Urology covers a wide range of conditions, and a single “Services” page cannot answer the questions patients bring. A page for each condition you treat, written in the words patients use, gives search engines and patients something specific to find. NIDDK, part of the National Institutes of Health, is a good reference for plain language. It describes kidney stones as hard, pebble-like pieces of material that form in one or both kidneys when high levels of certain minerals are in the urine, and it notes that you may hear them called renal calculi, nephrolithiasis or urolithiasis.

That second point matters for search. Patients type “kidney stone”, clinicians write “nephrolithiasis”, and a good page uses the patient term in the title and explains the clinical term once in the text. The same applies to “enlarged prostate” and “benign prostatic hyperplasia”, which NIDDK also calls BPH.

One page per condition: what it is in plain words, the symptoms that bring patients in, how your providers evaluate it, the categories of treatment your practice offers and how to book.
One page per procedure you want to be found for, with what to expect before, during and after, written from your own clinical protocols.
A provider page for each urologist and advanced practice clinician, with accurate credentials. Our guide to physician bio pages and board certification covers the wording.
A location page for each office and each place you perform procedures, so patients know where they will go.

Numbers on condition pages need the same care as any other claim. NIDDK states that about 11 percent of men and 6 percent of women in the United States have kidney stones at least once during their lifetime, and that experts estimate BPH affects 5% to 6% of men ages 40 to 64 and 29% to 33% of those ages 65 and older. If you quote figures like these, quote them exactly, name the source and link to it, and do not turn a population estimate into a statement about the reader.

Kidney stones: write for the patient in pain

A patient searching for kidney stone care may be in pain right now, so the page has to answer access questions first: whether you see new patients quickly, which locations and hours, whether a referral is needed, and how to reach the office. It also has to be safe. A practice website is not an emergency service, and the page should tell patients plainly when to call 911 or go to an emergency department, using wording your physicians approve.

NIDDK describes the main procedures in neutral terms. It explains that a doctor can use shock wave lithotripsy to break a kidney stone into small pieces that then pass through the urinary tract, as an outpatient procedure where anesthesia can be given, and it describes cystoscopy and ureteroscopy, where the doctor inserts a scope through the urethra, finds the stone and can remove it or break it into smaller pieces, in the hospital with anesthesia. It also notes that surgery sometimes causes complications, including infection. Pages that describe procedures this way, and say the provider recommends a plan after evaluation, are easier to defend than pages that promise a stone-free result.

Describe what each procedure is and what the day looks like. Do not promise that a stone will be cleared in one session or that patients will be pain free.
Do not claim a procedure is the fastest, best or safest option unless a qualified reviewer has confirmed you have evidence for that exact comparison.
If you list the equipment you use, describe it by type, not by marketing name, and check the FDA wording described in the next section.
If you offer stone prevention visits, describe the evaluation without promising that stones will not come back.

A clinic that runs a dedicated stone program, with same-day visits, prevention testing or posted prices, has more to get right than this section covers. Our guide to kidney stone clinic marketing covers the emergency wording, prevention and supplement claims, and cash price pages.

Prostate procedures and FDA device wording

Procedure pages that name a specific device depend on that device’s FDA status, which decides what you can say. NIDDK describes minimally invasive surgical therapies for BPH as procedures that remove enlarged prostate tissue or widen the urethra so urine flows more easily. Several of these device types have their own FDA classification regulations. When we read them on October 29, 2026, we found:

Implantable transprostatic tissue retractor systems (21 CFR 876.5530): a Class II prescription use device intended for the treatment of symptoms due to urinary outflow obstruction secondary to BPH.
Fluid jet systems for prostate tissue removal (21 CFR 876.4350): a Class II prescription device intended for the resection and removal of prostatic tissue for the treatment of BPH.
High intensity ultrasound systems for prostate tissue ablation (21 CFR 876.4340): a Class II prescription device that thermally ablates a defined, targeted volume of prostate tissue under imaging guidance. The regulation states that this classification does not include devices intended for the treatment of any specific prostate disease.
Extracorporeal shock wave lithotripters (21 CFR 876.5990): a Class II device that focuses shock waves into the body to fragment urinary stones within the kidney or ureter.

The third item shows why the exact words matter. A classification for ablating prostate tissue is not, on its own terms, a classification for treating a specific prostate disease. Before your site says any device is cleared, authorized or approved for a condition, ask the manufacturer for the FDA submission number and the exact indications for use, look the record up yourself in the FDA databases, and match your wording to it. Our guide to medical device marketing claims walks through cleared, authorized and approved in more detail.

Clearance itself has limits on how you describe it. Under 21 CFR 807.97, a premarket notification clearance does not in any way denote official approval of the device, and any representation that creates an impression of official approval because of the clearance is misleading and is misbranding. “FDA approved” is not a safe shorthand for a cleared device.

Prostate cancer screening: present it as a decision

PSA screening comes up on urology pages, in newsletters and at community events, and it is a subject where the federal guidance itself calls for a balanced message. The U.S. Preventive Services Task Force recommendation dated May 8, 2018 says that for men aged 55 to 69, the decision to undergo periodic PSA-based screening should be an individual one, and that men should have an opportunity to discuss the potential benefits and harms with their clinician. It recommends against PSA-based screening for men 70 and older. The archived copy of the page we read, from October 23, 2026, says the topic is being updated, so check the current page before you publish.

Messaging that says every man should get a PSA test, or that screening will catch cancer early and save your life, does not match that recommendation. A screening page that explains what the test is, who it may be appropriate for, that it is a decision to make with a clinician, and how to book a visit to talk it through, is consistent with it.

Coverage is a separate, factual point you can state if it applies to your patients. Medicare.gov says Part B covers digital rectal exams and PSA blood tests once every 12 months for men over 50, starting the day after their 50th birthday, and describes what the patient pays for each. Our guide to marketing to Medicare patients covers the wider rules for that audience. If you are planning a free or low-cost screening event, read our guide to health fairs and free screening events first, since free services offered to Medicare and Medicaid patients raise their own questions.

Vasectomy pages: plain facts about a permanent choice

Readers of a vasectomy page want to know what happens, how long recovery takes and what it costs. MedlinePlus, from the National Library of Medicine, gives a clear factual base. It describes vasectomy as surgery to cut the vas deferens, the tubes that carry sperm, most often done in the surgeon’s office using local anesthesia. It says the semen will be tested in the months after the operation to make sure it does not contain sperm, that vasectomy is not recommended as a short-term form of birth control, and that the procedure to reverse a vasectomy is a much more complicated operation, may not work, and may not be covered by insurance.

Do not call it painless. MedlinePlus says patients are awake with numbing medicine, and also that infection, swelling or prolonged pain can occur. Describe the anesthesia and the recovery instead.
Explain the follow-up semen test and what patients should do until it confirms there is no sperm, in wording your urologists approve.
Do not market reversal as a safety net. A page that implies a vasectomy can simply be undone conflicts with the plain facts above.
Describe technique accurately. MedlinePlus describes a no-scalpel vasectomy as one where a sharp instrument pierces the skin to make a single opening. Use that term only if your surgeons perform the procedure that way.
Price clearly. State what a quoted price includes, such as the consultation, the procedure and the follow-up test, and what it does not.

A clinic that runs a dedicated vasectomy program, with consult-first booking, the Medicaid consent waiting period and discreet semen test reminders, can use our guide to vasectomy clinic marketing.

Claims, testimonials and patient stories

Urology practices are not selling a product, but the same caution makes sense: the FTC approach generally requires that health-related claims be backed by competent and reliable scientific evidence. The FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce under 15 U.S.C. 45, and the FTC Health Products Compliance Guidance looks at the net impression of an ad, including claims implied by images and context. On a urology site, implied claims can come from words like “permanent fix”, “no more nighttime trips” or “back to normal in a day”.

Patient stories need two separate checks. Under 16 CFR 255.2(b), an endorsement about a key attribute of a service will likely be read as representing what people will generally achieve, so if a story is not representative, you need to clearly disclose what patients can generally expect. And because a testimonial tells the world that a person was your patient, using it in marketing generally requires a signed HIPAA authorization under 45 CFR 164.508(a)(3). Our guides to patient testimonials and patient photo and video consent cover the process.

Ads and tracking for urology services

Google’s Healthcare and medicines policy allows prescription drug ads only in select locations and from certain advertisers, restricts prescription drug terms in ads, landing pages and keywords, and says advertisers must apply to serve ads for prescription drug services. A urology practice that names prescription medicines in ads or on landing pages should check that policy before launching. Google’s personalized advertising policy also lists Health among its sensitive interest categories and says advertisers promoting products and services in those categories cannot use advertiser-curated audiences, such as remarketing lists.

Search campaigns built around clear, clinical keywords and matching condition pages fit those limits. Keep advertising pixels off booking forms and condition pages, so a visit to your incontinence or prostate page is not sent to ad platforms. Our guide to tracking pixels on practice websites explains why, and the Google Ads for practices page describes how we set up campaigns.

Illustration: reworking a prostate procedure page

Illustration. A urology practice has a page for a BPH procedure. It opens with “FDA approved, no more medication, back to normal tomorrow”, features a patient quote saying the procedure changed his life, and runs a remarketing campaign to everyone who visited the page.

FDA wording. The practice asks the manufacturer for the submission number, looks it up and finds a Class II clearance with a stated indication. “FDA approved” becomes “FDA cleared for” followed by that exact indication.
Results. “No more medication” and “back to normal tomorrow” come off. The page describes the procedure, the usual recovery steps from the practice’s own protocol and that the provider recommends a plan after evaluation.
Patient quote. The practice confirms it has a signed authorization. Because the quote is not representative of what patients can generally expect, it either adds a clear statement of typical experience that its clinicians can support or removes the quote.
Ads. The remarketing list is removed, the pixel comes off the page and the campaign runs on search keywords that match the condition page.

Checklist

One page per condition and procedure, in patient words, with clinical terms explained once.
Statistics quoted exactly, with the source named and linked.
Kidney stone pages that answer access questions and say when to seek emergency care.
Every device claim matched to the FDA record you looked up yourself, with no “FDA approved” for a cleared device.
PSA screening presented as a decision to make with a clinician, consistent with the current USPSTF page.
Vasectomy pages that explain the follow-up test, do not call the procedure painless and do not present reversal as a safety net.
No outcome promises, rankings or comparisons without evidence a qualified reviewer has checked.
Signed authorizations for every patient story, and a clear statement of typical experience when a story is not representative.
No remarketing lists for health topics, and no ad pixels on condition or booking pages.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices. For a urology practice, that means condition and procedure pages written in plain language from your own clinical protocols, device wording checked against the FDA record you provide, location pages for each office and procedure site, and campaigns set up without remarketing on health topics. Clinical content is reviewed and approved by your providers before it goes live. Our work is built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it.

Can we say a BPH procedure is FDA approved?

Only if the FDA record for that device says so. The BPH device types described above are classified as Class II, so check whether the record for your device shows a 510(k) clearance, a De Novo grant or a premarket approval. Under 21 CFR 807.97, a 510(k) clearance does not denote official approval, and implying approval because of it is misleading. Look up the submission number and use the exact status and indication.

Can we advertise focused ultrasound as a prostate cancer treatment?

Check the device record first. The FDA classification for high intensity ultrasound systems for prostate tissue ablation, 21 CFR 876.4340, states that it does not include devices intended for the treatment of any specific prostate disease. Your wording has to match what the FDA record for the specific device actually says.

Can we tell men to get a PSA test every year?

That message does not match the USPSTF recommendation dated May 8, 2018, which says the decision for men 55 to 69 should be an individual one made after discussing benefits and harms with a clinician, and recommends against PSA-based screening for men 70 and older. The page says the topic is being updated, so check it before you publish.

Can we call our vasectomy painless?

We would not. MedlinePlus says patients receive numbing medicine and also that infection, swelling or prolonged pain can occur. Describe the anesthesia, the procedure and the recovery instead.

Can we use a patient’s kidney stone story on our website?

Only with a signed HIPAA authorization under 45 CFR 164.508(a)(3), and with care under 16 CFR 255.2(b): if the story is not representative, clearly disclose what patients can generally expect.

Should our ED pages live on the same site as our urology pages?

That is a business choice. Either way, ED and male sexual health pages bring their own ad and wording rules, which our guide to male health and ED clinic marketing covers.

Urology practice marketing beyond ED: kidney stones, prostate care and vasectomy